Loading...
•
Dec 31, 2024
Organon Q4 2024 Earnings Report
Key Takeaways
Organon's Q4 2024 revenue remained stable at $1.592 billion, with growth in Established Brands offsetting declines in Biosimilars. Net income fell significantly due to a one-time tax benefit in Q4 2023.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Organon expects 2025 revenue between $6.125B and $6.325B, facing FX headwinds and Atozet’s loss of exclusivity. The company targets cost discipline to maintain an adjusted EBITDA margin of at least 31.0%.
Positive Outlook
- 2025 revenue expected to remain above $6.1B despite headwinds
- Adjusted EBITDA margin projected to improve to 31.0%-32.0%
- Continued expansion of Nexplanon and Hadlima sales
- Disciplined cost management to protect profitability
- Ongoing growth potential in women's health and biosimilars
Challenges Ahead
- Approx. $200M FX impact expected in 2025 revenue
- Loss of exclusivity for Atozet in key markets
- Competitive pricing pressure in biosimilars segment
- Higher inflation affecting material and distribution costs
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...